PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-0.50%
Cost reduction while CRVO shows 59.38% growth. Joel Greenblatt would examine competitive advantage.
41.00%
Positive growth while CRVO shows decline. John Neff would investigate competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-31.86%
R&D reduction while CRVO shows 59.38% growth. Joel Greenblatt would examine competitive risk.
-15.50%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.75%
Operating expenses reduction while CRVO shows 18.31% growth. Joel Greenblatt would examine advantage.
-27.36%
Total costs reduction while CRVO shows 18.31% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-0.50%
Both companies reducing D&A. Martin Whitman would check industry patterns.
28.32%
EBITDA change of 28.32% while CRVO is flat. Bruce Berkowitz would examine quality.
No Data
No Data available this quarter, please select a different quarter.
27.93%
Operating income growth exceeding 1.5x CRVO's 7.28%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-5.21%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
29.77%
Pre-tax income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
128.31%
Similar tax expense growth to CRVO's 129.91%. Walter Schloss would investigate patterns.
29.77%
Net income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
30.61%
EPS growth while CRVO declines. John Neff would investigate advantages.
30.61%
Similar diluted EPS growth to CRVO's 40.00%. Walter Schloss would investigate industry trends.
2.13%
Share count reduction exceeding 1.5x CRVO's 71.52%. David Dodd would verify capital allocation.
2.13%
Diluted share reduction exceeding 1.5x CRVO's 50.65%. David Dodd would verify capital allocation.